247 related articles for article (PubMed ID: 15887964)
1. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.
Cappelli A; Gallelli A; Manini M; Anzini M; Mennuni L; Makovec F; Menziani MC; Alcaro S; Ortuso F; Vomero S
J Med Chem; 2005 May; 48(10):3564-75. PubMed ID: 15887964
[TBL] [Abstract][Full Text] [Related]
2. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
[TBL] [Abstract][Full Text] [Related]
3. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
[TBL] [Abstract][Full Text] [Related]
4. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
5. Structure-affinity relationship studies on arylpiperazine derivatives related to quipazine as serotonin transporter ligands. Molecular basis of the selectivity SERT/5HT3 receptor.
Cappelli A; Giuliani G; Gallelli A; Valenti S; Anzini M; Mennuni L; Makovec F; Cupello A; Vomero S
Bioorg Med Chem; 2005 May; 13(10):3455-60. PubMed ID: 15848758
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands.
López-Rodríguez ML; Benhamú B; Morcillo MJ; Tejada I; Avila D; Marco I; Schiapparelli L; Frechilla D; Del Río J
Bioorg Med Chem; 2004 Oct; 12(19):5181-91. PubMed ID: 15351401
[TBL] [Abstract][Full Text] [Related]
7. New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
Fiorino F; Perissutti E; Severino B; Santagada V; Cirillo D; Terracciano S; Massarelli P; Bruni G; Collavoli E; Renner C; Caliendo G
J Med Chem; 2005 Aug; 48(17):5495-503. PubMed ID: 16107148
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
[TBL] [Abstract][Full Text] [Related]
9. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.
Rampa A; Bisi A; Valenti P; Recanatini M; Cavalli A; Andrisano V; Cavrini V; Fin L; Buriani A; Giusti P
J Med Chem; 1998 Oct; 41(21):3976-86. PubMed ID: 9767635
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors.
López-Rodríguez ML; Morcillo MJ; Fernández E; Benhamú B; Tejada I; Ayala D; Viso A; Campillo M; Pardo L; Delgado M; Manzanares J; Fuentes JA
J Med Chem; 2005 Apr; 48(7):2548-58. PubMed ID: 15801844
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type.
Kapková P; Stiefl N; Sürig U; Engels B; Baumann K; Holzgrabe U
Arch Pharm (Weinheim); 2003 Nov; 336(11):523-40. PubMed ID: 14639745
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
13. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
[TBL] [Abstract][Full Text] [Related]
14. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.
He XC; Feng S; Wang ZF; Shi Y; Zheng S; Xia Y; Jiang H; Tang XC; Bai D
Bioorg Med Chem; 2007 Feb; 15(3):1394-408. PubMed ID: 17126020
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity.
Wong DM; Greenblatt HM; Dvir H; Carlier PR; Han YF; Pang YP; Silman I; Sussman JL
J Am Chem Soc; 2003 Jan; 125(2):363-73. PubMed ID: 12517147
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
Belluti F; Rampa A; Piazzi L; Bisi A; Gobbi S; Bartolini M; Andrisano V; Cavalli A; Recanatini M; Valenti P
J Med Chem; 2005 Jun; 48(13):4444-56. PubMed ID: 15974596
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
[TBL] [Abstract][Full Text] [Related]
20. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
